Searching in Pharma & Drug Safety · Search everything
3,004 changes Pharma & Drug Safety
Viral and Non-Viral Nanoplasmid Vectors with Improved Production
USPTO granted patent US12600984B2 to Aldevron, L.L.C. covering methods for improving replication of covalently closed circular plasmids through replacement of Pol I-dependent origins with Pol III-dependent origins. The patent also claims antibiotic marker free covalently closed circular recombinant DNA molecules. The patent contains 31 claims.
Compositions and Methods for Controlling Production of Polypeptides in Cells
USPTO granted Patent US12600985B2 to the Board of Trustees of the Leland Stanford Junior University on April 14, 2026. The patent covers recombinant expression vectors with coding sequences flanked by recombinase recognition sites for modulating polypeptide production in target cells, along with associated methods and monitoring devices. Inventors include Karl A. Deisseroth, Charu Ramakrishnan, Yoon Seok Kim, and Lief E. Fenno. The patent contains 25 claims under CPC Classification C12N 15/85.
Vanderbilt Cyclopropylpiperidine M4 Antagonists - US12600726B2
The USPTO granted Patent No. US12600726B2 to Vanderbilt University on April 14, 2026, covering cyclopropylpiperidine compounds useful as antagonists of muscarinic acetylcholine receptor M4 (mAChR M4). The patent includes 15 claims and covers methods of making the compounds, pharmaceutical compositions, and methods of treating disorders using the compounds. Vanderbilt University receives enforceable IP rights for this therapeutic compound class.
Nanjing University of Chinese Medicine - US12600724B2 Indole Alkaloid Compound and Preparation Method
The USPTO granted Patent US12600724B2 to Nanjing University of Chinese Medicine for an indole alkaloid compound represented by formula (I), including its preparation method and pharmaceutical salts. The compound has demonstrated therapeutic effects in animal studies, including promoting axon growth in peripheral sensory neurons, improving nerve conduction velocity in diabetic rats, accelerating foot ulcer wound healing, reducing pulmonary fibrosis, and protecting lung tissues. The patent contains 13 claims covering the compound, formulations, and methods of treatment for diabetic complications.
ONO Pharmaceutical ABHD6 Antagonist Patent US12600730B2
USPTO granted Patent US12600730B2 to ONO Pharmaceutical Co., Ltd. on April 14, 2026, covering substituted cyclopenta[c]pyrrole compounds as ABHD6 antagonists for pharmaceutical use. The patent includes 18 claims for compounds useful in preventing or treating diseases associated with ABHD6 enzyme inhibition. The application was filed on April 8, 2024.
NURIX BTK Degrading Compounds, 36 Claims, Apr 14
The USPTO granted Patent US12600732B2 to NURIX THERAPEUTICS, INC. on April 14, 2026. The patent covers 36 claims for bifunctional compounds that degrade BTK via the ubiquitin proteolytic pathway, along with pharmaceutical compositions and methods of treatment for various diseases, conditions, or disorders.
Washington University Patent for Toxoplasma Gondii Treatment Compounds
The USPTO granted Patent US12600727B2 to Washington University on April 14, 2026, covering compounds and methods for treating infections caused by Toxoplasma gondii and related parasites. The patent includes 18 claims and lists inventors L. David Sibley, Joshua Radke, Eamon Comer, Marshall Morningstar, and Bruno Melillo. This grant provides Washington University with exclusive intellectual property rights for the developed antiparasitic compounds and their pharmaceutical applications.
ELI LILLY AND COMPANY - KRAS Inhibitor Compounds for Cancer Treatment Patent Grant
The USPTO granted Patent US12600733B2 to Eli Lilly and Company on April 14, 2026, covering KRAS inhibitor compounds for treating cancer. The patent includes 30 claims for compounds of specified formula and their use in pharmaceutical compositions. Filing date was September 30, 2025.
Tetracyclic DGK Inhibitor Compounds for Cancer Treatment
USPTO granted Patent US12600722B2 to Incyte Corporation for tetracyclic compounds that modulate diacylglycerol kinase (DGK) activity, useful in treating cancer including solid tumors. The patent names Joshua Hummel, Shicheng Shi, and Xiaozhao Wang as inventors and contains 63 claims.